Table 1.
Baseline characteristics for all patients and by KRAS mutation status
|
All patients |
KRAS wild-type group |
KRAS mutant group |
|||||
|---|---|---|---|---|---|---|---|
| Arm A (N=815) | Arm B (N=815) | Arm A (N=367) | Arm B (N=362) | Arm A (N=268) | Arm B (N=297) | ||
| Sex | |||||||
| Male | 525 (64%) | 543 (67%) | 245 (67%) | 253 (70%) | 169 (63%) | 192 (65%) | |
| Female | 290 (36%) | 272 (33%) | 122 (33%) | 109 (30%) | 99 (37%) | 105 (35%) | |
| Age | |||||||
| Median (years) | 63 (56–69) | 63 (58–70) | 63 (56–69) | 64 (59–70) | 63 (56–69) | 64 (58–70) | |
| >75 years | 74 (9%) | 72 (9%) | 31 (8%) | 30 (8%) | 28 (10%) | 27 (9%) | |
| WHO performance status | |||||||
| 0 | 375 (46%) | 376 (46%) | 177 (48%) | 171 (47%) | 114 (43%) | 135 (45%) | |
| 1 | 378 (46%) | 377 (46%) | 166 (45%) | 171 (47%) | 131 (49%) | 135 (45%) | |
| 2 | 62 (8%) | 62 (8%) | 24 (7%) | 20 (6%) | 23 (9%) | 27 (9%) | |
| Site of primary tumour | |||||||
| Colon | 453 (56%) | 444 (54%) | 210 (57%) | 197 (54%) | 145 (54%) | 163 (55%) | |
| Rectum | 243 (30%) | 262 (32%) | 101 (28%) | 119 (33%) | 90 (34%) | 93 (31%) | |
| Rectosigmoid junction | 113 (14%) | 106 (13%) | 56 (15%) | 46 (13%) | 32 (12%) | 41 (14%) | |
| Status of primary tumour | |||||||
| Resected | 445 (55%) | 420 (52%) | 218 (59%) | 188 (52%) | 157 (59%) | 173 (58%) | |
| Unresected | 331 (41%) | 346 (42%) | 131 (36%) | 148 (41%) | 97 (36%) | 107 (36%) | |
| Local recurrence | 39 (5%) | 49 (6%) | 18 (5%) | 26 (7%) | 14 (5%) | 17 (6%) | |
| Timing of metastases | |||||||
| Metachronous | 249 (31%) | 239 (29%) | 125 (34%) | 112 (31%) | 84 (31%) | 85 (29%) | |
| Synchronous | 552 (68%) | 569 (70%) | 236 (64%) | 246 (68%) | 180 (67%) | 212 (71%) | |
| No metastases | 7 (1%) | 6 (1%) | 4 (1%) | 5 (1%) | 3 (1%) | 0 | |
| Type of metastases | |||||||
| Liver only | 174 (21%) | 194 (24%) | 91 (25%) | 87 (24%) | 44 (16%) | 74 (25%) | |
| Liver plus others | 436 (53%) | 418 (51%) | 180 (49%) | 190 (52%) | 151 (56%) | 155 (52%) | |
| Non-liver | 198 (24%) | 197 (24%) | 92 (25%) | 80 (22%) | 70 (26%) | 68 (23%) | |
| Number of metastatic sites | |||||||
| 1 | 283 (35%) | 305 (37%) | 140 (38%) | 131 (36%) | 82 (31%) | 113 (38%) | |
| 2 | 326 (40%) | 311 (38%) | 140 (38%) | 139 (38%) | 116 (43%) | 115 (39%) | |
| >2 | 199 (24%) | 193 (24%) | 83 (23%) | 87 (24%) | 87 (32%) | 69 (23%) | |
| Previous treatment for metastases | |||||||
| Radiotherapy | 26 (3%) | 24 (3%) | 10 (3%) | 9 (2%) | 7 (3%) | 12 (4%) | |
| Surgery | 142 (17%) | 130 (16%) | 64 (17%) | 57 (16%) | 55 (21%) | 52 (18%) | |
| Alkaline phosphatase <300 U/L | 670 (82%) | 696 (85%) | 309 (84%) | 309 (85%) | 224 (84%) | 257 (87%) | |
| Platelet count <400 000 per μL | 564 (69%) | 549 (67%) | 259 (71%) | 251 (69%) | 189 (71%) | 189 (64%) | |
| White blood cell count <10 000 per L | 577 (71%) | 574 (70%) | 265 (72%) | 252 (70%) | 199 (74%) | 217 (73%) | |
Data are n (%) or median (IQR).